ELEV: Elevation Oncology, Inc. Stock

by  •  • Comments Off on ELEV: Elevation Oncology, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 202.16
Enterprise Value ($M) 142.34
Book Value ($M) 75.82
Book Value / Share 1.39
Price / Book 2.67
NCAV ($M) 74.74
NCAV / Share 1.37
Price / NCAV 2.70

Profitability (mra)
Return on Invested Capital (ROIC) -0.37
Return on Assets (ROA) -0.51
Return on Equity (ROE) -1.17

Liquidity (mrq)
Quick Ratio 46.22
Current Ratio 46.22

Balance Sheet (mrq) ($M)
Current Assets 107.89
Assets 108.96
Liabilities 33.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -40.34
Net Income -45.70

Cash Flow Statement (mra) ($M)
Cash From Operations -56.18
Cash from Investing 11.54
Cash from Financing 47.98

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-09 13G Frazier Life Sciences Public Fund, L.P. 6.10
02-14 13G/A K2 HealthVentures Equity Trust LLC 4.00 13.90
02-14 13G/A Cormorant Asset Management, LP 0.00 -100.00
02-14 13G/A Biotechnology Value Fund L P 9.99 92.50
02-14 13G Orbimed Advisors Llc 6.80
02-14 13G/A Tang Capital Partners Lp 9.99 217.18
02-14 13G/A Point72 Asset Management, L.P. 9.40 90.46
02-07 13G/A ExodusPoint Capital Management, LP 0.10 -96.47
02-06 13G/A Aisling Capital IV, LP 6.80 0.06
01-31 13G/A Integrated Core Strategies (us) Llc 7.10 113.99
01-22 13G Farallon Capital Partners, L.P. 7.30
01-22 13G Logos Global Management LP 8.60
01-09 13G/A Qiming U.S. Healthcare GP II, LLC 0.00 -100.00
01-09 13G Empery Asset Management, LP 6.70
06-15 13D/A venBio Global Strategic Fund III, L.P. 6.10 35.98

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-06 58,411 432,962 13.49
2024-05-03 47,418 431,646 10.99
2024-05-02 204,335 521,222 39.20
2024-05-01 886,857 451,637 196.37

(click for more detail)

Similar Companies
DSGN – Design Therapeutics, Inc. DVAX – Dynavax Technologies Corporation
EDIT – Editas Medicine, Inc. ELVN – Enliven Therapeutics, Inc.
ENTA – Enanta Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io